SDZ281-977(Synonyms: SDZ-LAP 977)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

SDZ281-977 (Synonyms: SDZ-LAP 977)

SDZ 281-977 是 EGF 受体酪氨酸激酶抑制剂 Lavendustin A 的衍生物。

SDZ281-977(Synonyms: SDZ-LAP 977)

SDZ281-977 Chemical Structure

CAS No. : 150779-71-8

规格 是否有货
5 mg Check price and availability
10 mg Check price and availability
25 mg Check price and availability
50 mg Check price and availability

* Please select Quantity before adding items.

SDZ281-977 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library

生物活性

SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.

体外研究
(In Vitro)

The anticancer profile of SDZ 281-977 is investigated in nude mice bearing the human tumor cell lines A431 (vulvar carcinoma cells), MIA PaCa-2 (pancreatic tumor cells) and MDA-MB-231 (breast carcinoma cells). These cell lines are selected because of their sensitivity for SDZ 281-977. The IC50 values for inhibition of growth of A431, MIA PaCa-2 and MDA-MB-231 cells are 0.21 μM, 0.29 μM and 0.43 μM, respectively[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. Orally administered SDZ 281-977 (30 mg/kg) induces a 54% inhibition of A431 tumor growth after 3 weeks of treatment. The above regimens are well tolerated. No significant change in body weight occurred during treatment[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

316.35

Formula

C18H20O5

CAS 号

150779-71-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (316.11 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1611 mL 15.8053 mL 31.6106 mL
5 mM 0.6322 mL 3.1611 mL 6.3221 mL
10 mM 0.3161 mL 1.5805 mL 3.1611 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 2.5 mg/mL (7.90 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (7.90 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (7.90 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.90 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (7.90 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.90 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Cammisuli S, et al. SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Int J Cancer. 1996 Jan 26;65(3):351-9.

Cell Assay
[1]

Tumor cell lines are grown at 37°C under optimal medium and cell concentration conditions in the absence of antibiotics. At the time of exponential growth for tumor cell lines growing in suspension or at the time of 60-90% confluence for adherent cell lines, cells are harvested (adherent cell lines are trypsinized), suspended in fresh growth medium and seeded into 96-well cell culture plates at concentrations ranging between 1000 and 5000 cells/well. Cells are grown at optimal initial concentration for 3-4 days in a final volume of 0.2 ml/well in the presence of graded concentrations of test compounds. Extent of cellular proliferation is measured by a colorimetric assay using MTT for cells growing in suspension or by sulforhodamine B (SRB) for adherent cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]
Female nude mice (nu/nu IFFA C BALB A) weighing 20-23 g are used. For i.v. studies, SDZ 281-977 (10 mg) is dissolved in 1 mL Vepesid solvent (3250 mg PEG 300, 10 mg citric acid, 400 mg Tween 80 and 1205 mg ethanol). This solution is diluted with saline or Vepesid solvent/saline 1:10 so that all animals intravenously receive 0.2 mL of 1:10 Vepesid solvent containing 1, 3 and 10 mg SDZ 281-977/kg. Higher doses are not given due to limited solubility. SDZ 281-977 is injected into the tail vein 3 or 4 times a week. For oral testing, SDZ 281-977 is dissolved in Placebo G (18% ethanol, 43% Labrafil M2125CS and 39% corn oil) and 0.2 mL is given orally with a gavage. Control animals are treated with the vehicle only. For the comparative experiments, standard anticancer drugs are dissolved in saline containing 1% Tween 80 and water, respectively, and are injected i.p. once a day for 4 days in a row. Treatment started 2 days after animals have been randomized.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Cammisuli S, et al. SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Int J Cancer. 1996 Jan 26;65(3):351-9.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务